ACHV Nasdaq Earnings call
Achieve Life Sciences, Inc. (ACHV) · Q1 2026 results
Share price: $6.78 · 2026-11-11
Results Q1 2026 vs Q4 2025 · previous quarter · published 12 May 2026 and 24 Mar 2026
Net loss narrowed on the previous quarter. Management sounded restrained, in its script and in answers to analysts.
Only a basic analysis is available for this company at the moment.
1 · Numbers
Loss narrowed
Net income vs Q4 2025
Net income -10.2M vs -14.7M
Net income -10.2M vs -12.8M in Q1 2025 and -14.7M last quarter.
2 · How management spoke
Restrained
Less upbeat than 71% of company calls
Answers to analysts: restrained, in line with the script.
Similar to last call.
3 · What stood out
Figure
Smoking remains the leading cause of preventable death in the U.S., claiming approximately 500,000 lives annually and costing over $600 billion.
Valuation
Reverse DCF. Free cash flow from the last full fiscal year, grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.
Valuation unavailable: free cash flow and profit were negative in the last full year and on average over the last three, so there is nothing to discount.
Current price
$6.78
close of 2026-11-11
Free cash flow 2024
−$0.0B
Free cash flow 2025
−$0.0B
Read between the lines
-
Fading
Secondly, Achieve's vaping cessation indication was one of the first recipients of the Commissioner's National Priority Voucher.
Source quote
“Secondly, Achieve's vaping cessation indication was one of the first recipients of the Commissioner's National Priority Voucher. ...New Drug Application or NDA for the smoking cessation indication and its acceptance by the FDA, moving us one important step closer to becoming the first new FDA-approved treatment in 20 years. Recognition of cytisinicline as a national priority is an incredible achievement of the work conducted by Achieve and the importance of cytisinicline in tackling the previously intractable problem of nicotine dependence.”
-
Dropped
The company is no longer emphasizing three critical value drivers as it focuses on the launch of cytisinicline for smoking cessation following its NDA approval.
Source quote
“As we look ahead, I want to highlight 3 critical value drivers for our Company. In closing, I'm pleased with our regulatory, clinical, and go-to-market efforts, which underscores the momentum behind Achieve Life Sciences and our unwavering commitment to addressing the critical unmet needs of nicotine dependence. First, receiving NDA approval and successfully launching cytisinicline for smoking cessation.”
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q1 2026. Ring: Q4 2025.
Script and answers carried a similar tone, so the script's message held up under questioning.
Sentences that drove the tone
“At Achieve, the strength of the clinical data and the favorable tolerability profile gave me conviction that we have an opportunity to fill that gap between patient need and available...”
“Together with Chris, this team brings deep experience from, Ohtuvayre, widely regarded as one of the best launches in industry history, and we are thrilled to have their leadership for...”
“In closing, my focus now is on growing our team and executing the strategy required to launch this important medicine at the scale the opportunity deserves.”
Full figures
USD · ROIC.AI fundamentals (NASDAQ:ACHV, period end 2026-03-31)
| Metric | Q1 2026period end 2026-03-31 | Q4 2025period end 2025-12-31 | Change | Q1 2025 | YoY |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | ||
| Operating income | -10.5M | -14.7M | Loss narrowed | -12.9M | Loss narrowed |
| Net income | -10.2M | -14.7M | Loss narrowed | -12.8M | Loss narrowed |
| EPS | -0.19 | -0.28 | Loss narrowed | -0.37 | Loss narrowed |
| P/E | 12-mo loss | 12-mo loss | — | 12-mo loss | — |
Topics
Most discussed now
- New My expertise is helping companies cross the chasm from late-stage development to commercial with disciplined execution, all in service of...
- Improving patient care has been the focus of my career.
- It's been with the lack of an effective and tolerable therapy that prescribers feel confident offering.
Faded since Q4 2025
- Dropped It does afford us a bit more time to get a few other operational things activated as well.
- Fading The positive data on COPD patients highlights the expansive scope of opportunities for cytisinicline in terms of the range of...
- Dropped Regarding timing, the actual clock really starts building for the demand when the drug is in channel.
- Dropped Achieve Life Sciences really do believe that it is at this brink on the brink of actually great success and having the ability...
Latest announcements
Official filings, newest first.
- Director or officer change · SEC 8-K
- Other events · SEC 8-K
- Results of operations · SEC 8-K
- Articles or bylaws amended; Shareholder vote results · SEC 8-K
- Director or officer change · SEC 8-K
- Results of operations; Director or officer change · SEC 8-K
- Material agreement; Unregistered share sale; Director or officer change; Regulation FD disclosure · SEC 8-K
- Results of operations · SEC 8-K